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2Abstract1
Despite pharmacological treatment, bronchial hyperresponsiveness continues to2
deteriorate as airway remodelling persists in airway inflammation. Previous studies3
have demonstrated that the phytocannabinoid ∆9-tetrahydrocannabinol (THC)4
reverses bronchoconstriction with an anti-inflammatory action. The aim of this study5
was to investigate the effects of THC on bronchial epithelial cell permeability after6
exposure to the pro-inflammatory cytokine, TNFα. 7
Calu-3 bronchial epithelial cells were cultured at air-liquid interface. Changes in8
epithelial permeability were measured using transepithelial electrical resistance9
(TEER), then confirmed with a paracellular permeability assay and expression of10
tight junction proteins by Western blotting.11
Treatment with THC prevented the TNFα-induced decrease in TEER and increase in 12
paracellular permeability. Cannabinoid CB1 and CB2 receptor-like immunoreactivity13
was found in Calu-3 cells. Subsequent experiments revealed that pharmacological14
blockade of CB2, but not CB1 receptor inhibited the THC effect. Selective stimulation15
of CB2 receptors displayed a similar effect to that of THC. TNFα decreased 16
expression of the tight junction proteins occludin and ZO-1, which was prevented by17
pre-incubation with THC.18
These data indicate that THC prevents cytokine-induced increase in airway epithelial19
permeability through CB2 receptor activation. This highlights that THC, or other20
cannabinoid receptor ligands, could be beneficial in the prevention of inflammation-21
induced changes in airway epithelial cell permeability, an important feature of22
airways diseases.23
3Keywords: Airway, epithelium, cannabinoid receptors, THC, tight junctions.1
2
Chemical compounds studied in this article:3
∆9-tetrahydrocannabinol (PubChem CID: 16078); AM251 PubChem CID: 2125;4
SR144528 (PubChem CID: 3081355); HU-210 (PubChem CID: 9821569); ACEA5
(PubChem CID: 5311006); JWH133 (PubChem CID: 6918505)6
7
Abbreviations: ∆9-Tetrahydrocannabinol, THC; ALI, air-liquid interface; CB18
receptor, cannabinoid receptor 1; CB2, cannabinoid receptor 2; DMSO,9
dimethylsulfoxide; EtOH, ethanol; EVOM2, epithelial volt-ohm-meter version 2;10
interleukin-1β, IL-1β; LLI, liquid-liquid interface; TEER, Transepithelial Electrical 11
Resistance;  TNFα, tumour necrosis factor-α, ZO, zonula occludens. 12
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41 Introduction1
The airway epithelium provides a physical barrier, which prevents harmful agents2
from penetrating into the smooth muscle compartment and activating inflammatory3
responses [1]. This barrier function is regulated by tight junctions between cells,4
comprising of a complex of proteins, including occludin, claudin, junctional adhesion5
molecules, and zonula occludens (ZO-1, ZO-2, and ZO-3) [2]. Reduced expression6
of these proteins results in altered tight junction function, increased epithelial7
permeability and, consequently, increased transit of pro-inflammatory mediators and8
cytokines, leading to stimulation of the afferent sensory nerves and airway9
hyperreactivity [3]. Cytokines, such as TNFα have been shown to lead to loss of 10
occludin staining, which is associated with increased epithelial permeability [4].11
Therefore, regulation of tight junction protein expression and hence airway epithelial12
permeability is a target for preventing aggravation or progression of inflammatory13
airway diseases such as asthma [5]. Interestingly, tight junction disruption is present14
in biopsies from patients with asthma irrespective of treatment suggesting that15
current treatments for asthma may not prevent epithelial dysfunction [6]. ∆9-16
tetrahydrocannabinol (THC), the main phytocannabinoid derived from the Cannabis17
plant, binds readily to both CB1 and CB2 receptors as a partial agonist [7].18
Cannabinoid receptors have been shown to have anti-inflammatory effects in the19
airways. For example, THC prevents the enhanced nerve-evoked airway20
contractions in guinea pig trachea exposed to TNFα [8] through stimulation of both 21
CB1 and CB2 cannabinoid receptors. The cannabinoid receptor agonist CP55,94022
prevents inflammation-induced bronchoconstriction and mast cell degranulation in23
ovalbumin-sensitised guinea-pigs [9] and the endocannabinoid anandamide reverses24
leukotriene D4-induced airway constriction [10]. Although the effects of THC on25
5inflammation-induced changes in airway epithelial permeability are unknown, it has1
recently been shown that THC reverses the increase in colonic epithelial2
permeability caused by cytokines through activation of CB1 receptors [11]. It is not3
known whether the effects of THC on colonic epithelial cells can be replicated in4
airway epithelial cells and, hence, whether cannabinoid receptor agonists might be5
exploited therapeutically to reverse the increase in airway epithelial permeability as6
seen in airway inflammation. Therefore, this present study determined the effect of7
THC on TNFα-induced increase in permeability and reduced tight junction protein 8
expression in airway epithelial cells.9
10
62 Materials and Methods1
2.1 Cell culture2
Calu-3 cells obtained from ATCC (Rockville, MD, USA) were cultured (from3
passages 5 to 20) on polyester membrane of Transwells® (pore size 0.4 µm, inserts4
surface area 1.12 cm2) (Corning CoStar, Arlington, UK). Cell culture medium,5
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F12 Ham contained 10% of6
fetal bovine serum, 1% L–glutamine 1% non-essential amino acids, and 1%7
penicillin/streptomycin. Cells were seeded at a density of 1 x 105 cells per well until8
day 5 until confluent. Medium from the apical and basolateral side were removed9
and washed with 0.5 ml of phosphate-buffered saline (PBS) every 2 to 3 days. Air-10
liquid interface (ALI) was established and maintained for three weeks, at which only11
the basolateral compartment was replaced with medium.12
13
2.2 Transepithelial Electrical Resistance (TEER) Measurements14
Changes in Calu-3 epithelial permeability were assessed by measuring TEERs using15
STX2 electrodes (World Precision Instruments, Stevenage, UK). Prior to TEER16
measurement, the apical face of cells were washed with 0.5 ml warmed PBS. Basal17
(i.e. time zero) TEER was recorded after replacing the basolateral and apical18
compartments of Transwells® with 1.5 ml and 0.5 ml respectively. The resistance19
expressed by Calu-3 cells alone was obtained by subtracting resistance of the filter20
membrane. TEER values were presented as epithelial resistance per cm2 of21
Transwells® membrane.22
The effect of THC on cytokine-induced bronchial epithelial permeability was23
determined by pre-treating the cells with THC (3, 10 or 30 μM) or vehicle control 24
7(0.3% v/v EtOH) basolaterally, prior to addition of TNFα (10 ng/ml) or IL-1β (1 ng/ml). 1
TEERs were measured at various time points up to 48 hours post-drug application.2
In some experiments, AM251 (100 nM) and SR144528 (100 nM) were included to3
determine the role of CB1 and CB2 receptors respectively in the THC response. The4
involvement of cannabinoid receptor was further investigated using the potent5
cannabinoid receptor agonist, HU-210 (100 nM) and selective CB1 or CB2 receptor6
agonists ACEA (100 nM) and JWH133 (3 µM) respectively.7
8
2.3 Paracellular Permeability Assay using Fluorescein Isothiocyanate (FITC)9
Dextran10
Changes in epithelial permeability were confirmed by measuring transfer of FITC-11
labelled dextran (4 kDa) across the epithelial layer. In these experiments, media on12
the apical side was removed and replaced with 0.3% (w/v) N-acetyl cysteine (NAC),13
dissolved in warm (37⁰C) medium, to remove the apical mucus layer. After 3014
minutes, NAC was aspirated and 500 μg/mL of FITC-dextran in warm medium added 15
and cells incubated at 37oC. Permeability of the epithelial layer was estimated by16
sampling 100 μl of basolateral medium at basal, then every 30 minutes, for up to 3 17
hours. The amount of FITC-dextran present in the basolateral solution was18
determined by measuring the fluorescence intensity using a FluoStarGalaxy®19
fluorometer, set at wavelengths 485 nm (excitation) and 520 nm (emission). The20
apparent permeability coefficient (Papp) is calculated according to the following21
equation:-22
Papp=
( ∆Q
∆t )
A.C0
8Where Papp is the apparent permeability coefficient (cm/sec)1
ΔQ is the change in FD4 concentration over time (Δt) 2
A is the surface area of the Transwell filter (1.12cm2)3
C0 is the initial concentration of FD4 applied to the apical side of the cells (500µg/ml)4
2.4 Western blot analysis5
Treated cells were lysed with 200 µl lysis buffer (20 mM Tris, 1 mM sodium fluoride,6
1 mM ethyleneglycoltetraacetic acid (EGTA), 0.1% (v/v) Triton X100 and 10 mM β-7
glycerophosphate, pH 7.6) with protease inhibitor cocktail (Sigma Aldrich, Dorset,8
UK). Lysates were centrifuging at 6000 x g at 4⁰C for 5 minutes. Supernatants were9
removed and diluted with 6 x Laemmli buffer and then heated at 95⁰C for 5 minutes.10
Samples (10 µl) were separated using a 4%-20% precast SDS-PAGE gel and then11
transferred onto nitrocellulose membrane by Western blotting. After transfer,12
membranes were blocked in 5% w/v fat-free milk dissolved in Tris-buffered saline13
solution containing 0.1% v/v Tween-20 (TBS-T) for 1 hour. The membrane then was14
probed overnight at 4oC with one of the following primary antibodies in blocking15
buffer: anti-occludin rabbit antibody (ab31721; Abcam, Cambridge, UK), anti-ZO-116
rabbit antibody (40-2200) (Zymed, San Francisco, USA), anti-CB1 receptor antibody17
(1006590, Cayman Chemical, Michigan, USA) and anti-CB2 receptor antibody (ADI-18
905-749-100, Enzo Life Sciences, New York, USA). Membranes were also probed19
with anti-GAPDH mouse antibody at 1:20,000 dilution (Sigma Aldrich, Dorset, UK) as20
a loading control. The following day, primary antibodies were removed and21
membranes washed three times with TBS-T buffer. Membranes were then incubated22
with secondary antibodies (both at 1:10,000 dilution); goat anti-rabbit IgG23
(IRDye®800CW Conjugate, Licor Biosciences, Cambridge, UK) and goat anti-mouse24
9IgG (IRDye®680CW Conjugate, Licor Biosciences, Cambridge, UK), as appropriate.1
After washing with TBS-T buffer, bands were detected and quantified using LI-COR2
Image Studio infrared imaging system (Lincoln, NE).3
2.5 Statistical Analysis4
Time-dependent changes in TEER were analysed using a 2-way ANOVA, followed5
by a Bonferroni post-hoc test, using GraphPad Prism. Western blotting data were6
analysed by 1-way ANOVA followed by a Bonferroni post-hoc test. Results of p<0.057
were considered significant.8
2.6 Materials9
THC, AM251, SR144528 were obtained from Tocris Bioscience (Bristol, UK). All10
other reagents were obtained from Sigma Aldrich (Dorset, UK).11
10
3 Results1
3.1 Effect of THC on Cytokine-Induced Reductions in TEER2
Basolateral application of THC alone at 3 and 10 µM had no effect on the3
Transepithelial electrical resistance (TEER) reading in Calu-3 airway epithelial cells4
(fig. 1). At 30 µM THC, there was a small increase in TEER (fig. 1). Resistance5
readings for vehicle control 0.3% (v/v) EtOH were maintained throughout the whole6
duration of experiment. In other experiments, THC was added 24 hours after addition7
of TNFα (10 ng/ml; fig. 2). In these experiments, TNFα caused a reduction in TEER 8
over the first 24 hours, which was reversed by the subsequent addition of THC (309
µM). In cells treated with TNFα alone, the reduction in TEER was maintained for the 10
duration of the experiment (up to 48 hours post TNFα addition; fig. 2 & 3A). Pre-11
treatment with THC reduced the effect of TNFα on TEER responses in a 12
concentration-dependent manner (Fig. 3A). Similarly, pre-treatment with THC13
reduced the subsequent reduction in TEER as a result of IL-1β treatment, although 14
the effect of IL-1β was not completely prevented (fig. 3B).   15
16
3.2 Effect of THC on FITC-Dextran Permeability17
Treatment with TNFα alone produced an increase in FD4 dextran paracellular 18
permeability (fig. 4). The basolateral application of THC alone did not alter FD419
dextran permeability through the Calu-3 cell layers. However, the increase in FD420
dextran permeability caused by TNFα was prevented in the presence of THC. These 21
data thus confirmed the correlation that a decrease in TEER is mirrored by an22
increase in Papp.23
24
11
3.3 Role of Cannabinoid Receptors in THC-Mediated Effect1
In order to determine whether the effect of THC was mediated through cannabinoid2
receptor activation, the effects of either the CB1 receptor antagonist AM251 (100 nM;3
[12]), or the CB2 receptor antagonist SR144528 (100 nM; [13]) were determined. As4
in previous experiments, TEER responses in the presence of TNFα (10 ng/ml) with 5
THC (30 µM) were maintained around vehicle control levels over the duration of the6
experiment. The presence of SR144528 (fig. 5B), but not AM251 (fig. 5A) prevented7
the inhibitory effect of THC on the TNFα-induced reduction in TEER (fig. 5). 8
9
In order to determine whether CB receptor-selective agonists are able to replicate10
the effect of THC, the CB1/2 receptor agonist HU-210 (100 nM), the selective CB111
receptor agonist ACEA (100 nM), or the selective CB2 receptor agonist JWH 133 (312
μM) were used. None of these agonists had any effect on TEER responses on their 13
own over the 48 hour duration of the experiment (fig. 6A). However, pre-incubation14
with either HU-120 or JWH 133 prevented the reduction in TEER caused by TNFα 15
(10 ng/ml; fig. 6B). Pre-incubation with ACEA did not prevent the immediate effects16
of TNFα. However, in cells treated with ACEA, the TEERs returned to baseline within 17
24 hours, whereas in TNFα-treated cells TEERs remained low (fig. 6B).  18
19
3.4 CB Receptors Expression in Calu-3 Cells20
Western immunoblotting detected bands for both CB1 and CB2 receptors at the21
appropriate molecular weights (fig. 7 A&B). Rat cerebellum, used as a positive22
control for CB1 receptor expression, exhibited two major bands of slightly higher23
molecular weight than that seen in Calu-3 cells. No bands were seen in BV-2 cells,24
used as a negative control for CB1 expression. The band obtained with the anti-CB225
12
receptor antibody corresponded to the band obtained with rat spleen, used as a1
positive control. No band was seen in SH-SY5Y cells, used as a negative control.2
Expression of both receptors appeared to be increased in cells grown at air-liquid3
interface compared to cells grown at liquid-liquid interface (fig. 7 A & B).4
5
3.5 Effect of THC on TNFα-Induced Alteration of Occludin and ZO-1 Expression 6
Western blotting detected a band for occludin at around 64 kDa, whereas ZO-1 was7
expressed at approximately 225 kDa (fig. 8A & 9A). Other bands of lower molecular8
were also obtained, as observed by other groups using Calu-3 cells [14] (Wan et al.,9
2000). TNFα (10 ng/ml) reduced the expression of occludin and ZO-1 by half, 10
compared to untreated (basal) Calu-3 cells (fig. 8B & 9B). Treatment with THC alone11
had no effect on the expression of either occludin or ZO-1, but prevented the12
decrease in expression caused by TNFα (fig. 8 & 9).  13
14
13
4 Discussion1
The phytocannabinoid THC has been previously shown to improve airway function in2
asthmatic patients [15] and activation of cannabinoid receptors prevents3
inflammation-induced changes in the airways [9]. Airway inflammation leads to4
increased permeability of the epithelial layer, resulting in a loss of barrier function,5
which is thought to be involved in development of airway hyperreactivity. This6
present study has demonstrated that pre-treatment with THC prevents the increase7
in permeability across a confluent monolayer of Calu-3 airway epithelial cells caused8
by the cytokines TNFα and IL-1β. THC appeared to have more of a protective effect 9
against TNFα compared to IL-1β, which may be related to differences in the 10
signalling pathways activated by these two cytokines. Interestingly, THC added 2411
hours after the addition of TNFα reverses the increase in epithelial permeability. The 12
effect of THC was inhibited by a CB2 receptor antagonist and mimicked by a13
selective CB2 receptor agonist. Both TNFα and IL-1β are important inflammatory 14
cytokines involved in airway inflammation in both asthma and COPD [16, 17, 18].15
Therefore, these data suggest that cannabinoid receptor ligands, particularly CB216
agonists, could play a role in preventing or reversing inflammation-induced increases17
in airway epithelial permeability, and, hence, preventing airway hyperreactivity.18
19
Previous investigations have demonstrated an inverse relationship between20
paracellular permeability of Calu-3 cells cultured at ALI and TEER measurements,21
whereby an increase in paracellular transport of solutes through the bronchial22
epithelial cell layer is mirrored by a decrease in transepithelial resistance reading23
[19, 20, 21]. Results obtained from the present study showed a marked increase in24
paracellular permeability (i.e. high Papp value) in Calu-3 cells treated with TNFα, 25
14
which was prevented by pre-treatment with THC (fig. 4). These data thus confirm1
that the changes in TEER reflect an increase in paracellular permeability of the2
epithelial cells, and vice versa.3
4
The involvement of CB1 and CB2 receptors as the potential site of action of THC was5
assessed using the selective cannabinoid receptor antagonists, AM251 [22] and6
SR144528 [13]. SR144528, but not AM251, inhibited the THC-induced response in7
Calu-3 bronchial epithelial cells, suggesting that the action of THC in preventing the8
decrease in epithelial permeability by TNFα was mediated through CB2 receptors.9
Immunoreactivity with antibodies against CB1 and CB2 receptors was also detected10
in samples from Calu-3 cells, indicating the presence of both receptor subtypes.11
Interestingly, expression of both receptors was apparently higher in cells grown at12
ALI compared to cells grown at liquid-liquid interface (LLI). An ultrastructure study13
reported by a separate group of investigators revealed that ALI enhanced the14
differentiation of Calu-3 cells into a mucociliary phenotype, which was not seen in LLI15
[23]. Therefore, growing cells at ALI may have promoted the CB receptor expression16
demonstrated in the present study.17
18
In order to investigate the role of CB receptor subtypes further, TEER measurements19
were conducted using CB receptor-selective agonists. HU-210, a highly selective20
cannabinoid receptor agonist that acts on both CB1 and CB2 receptors in the21
nanomolar range [24], prevented the TNFα-induced decrease in TEER, in a similar 22
manner to THC. JWH133, a highly-selective CB2 receptor agonist [25] also23
prevented the effect of TNFα. On the other hand, ACEA, a selective CB1 receptor24
agonist [26], did not prevent the immediate TEER reduction as seen with TNFα, but 25
15
caused a reversal of the TNFα-effect after 24 hours. It is possible, therefore, that CB21
receptors mediate acute reversal of the TNFα-induced reduction in TEER, whereas 2
CB1 receptor activation requires chronic activation. However, the CB2 agonist does3
not completely prevent the reduction in TEER with TNFα and still requires 3-4 hours 4
to reverse the response suggesting it reverses rather than prevents the TNFα 5
response. A previous study has indicated that CB2 receptors prevent TNFα-induced 6
release of IL-8 from airway epithelial cells, potentially through a cAMP-mediated7
alteration in gene expression [27]. Therefore, it is possible that the delayed effect of8
the CB2 agonist in this present study is due to the time required to alter gene9
expression.10
11
The expression of epithelial tight junction proteins such as occludin and ZO-1 are12
directly linked to the transepithelial resistance of the Calu-3 bronchial epithelial cell13
line [28]. Previous studies in the same cell model have demonstrated a decrease in14
Calu-3 cell transepithelial resistance following the exposure to TNFα, accompanied 15
by reduced immunoreactivity against occludin and ZO-1 proteins [29]. In the present16
study, Western blotting demonstrated that the reduction in the level of both occludin17
(fig. 8) and ZO-1 (fig. 9) expression when cells were treated with TNFα could be 18
prevented by pre-treatment with THC. THC alone had no effect on the expression of19
the tight junction proteins. This is consistent with the changes in TEERs and the20
permeability assay. The effect of THC could be to inhibit the TNFα signalling 21
pathway leading to a reduction in occludin and ZO-1 expression, or it could be acting22
through a separate pathway which counteracts the changes in tight junction proteins.23
The fact that THC reverses the TNFα-induced reduction in TEER 24 hours after 24
16
addition of TNFα, suggests that it may be reversing rather than preventing the 1
changes in protein expression.2
3
In summary, these data indicate that THC, through activation of cannabinoid4
receptors and subsequent prevention of decreases in tight junction protein5
expression, has the ability to inhibit cytokine-induced airway epithelial barrier6
function disruption. Reduced barrier function is associated with hyperreactivity of the7
airways in inflammation. Therefore, epithelial cannabinoid receptors may be a8
therapeutic target for the prevention of airway epithelial dysfunction, as seen in9
asthma and COPD.10
11
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1
Figure 1 THC has little direct effect on TEER.
Effects of basolateral application of at various THC concentrations (3, 10 and
30 µM) or vehicle control, 0.3% v/v EtOH onto 21-day old Calu-3 cells.
Average basal TEER value was 695±2.8 Ω.cm2. Data are expressed as
percentage TEER by calculating the relative change in resistance at various
time points from basal reading, and are presented as mean ± SD; n=9,
**P<0.01, 2-way ANOVA followed by a Bonferroni post-hoc test, compared to
vehicle, 0.3% v/v EtOH, except THC + cytokine which is compared to TNF(10
ng/mL).
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Figure 2 THC reverses the decrease in TEER caused by TNFα. 1
Effect of basolateral application of THC (30 µM) alone or vehicle control, 0.3% v/v2
EtOH onto 21-day old Calu-3 cells 24 hours after application of 10ng/ml TNFα. 3
Average basal TEER value was 721±6.1 Ω.cm2. Data are expressed as percentage4
TEER by calculating the relative change in resistance at various time points from5
basal reading, and are presented as mean ± SD; n=9, ***P<0.001, 2-way ANOVA6
followed by a Bonferroni post-hoc test, compared to vehicle, 0.3% v/v EtOH, except7
THC + cytokine which is compared to TNF(10 ng/mL).8
9
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Figure 3 THC prevents decrease in TEER caused by TNFα and IL-1β.1
Effects of basolateral application of THC (at 3, 10 or 30 µM) in the presence of a2
cytokine, A. TNFα (10 ng/ml) or, B. the effect of basolateral application of THC (303
µM) in the presence of IL-1β (1 ng/ml) onto 21-day old Calu-3 cells cultured in ALI. 4
Average basal TEER values were A. 700±2.3 Ω.cm2 and B. 690±3.4 Ω.cm2. Data5
are expressed as percentage TEER by calculating the relative change in resistance6
at various time points from basal reading, and are presented as mean ± SD; n=9-15,7
*P<0.05, **P<0.01, ***P<0.001, 2way ANOVA followed by a Bonferroni post-hoc test,8
compared to vehicle, 0.3% v/v EtOH, except THC + cytokine which is compared to9
their respective cytokine.10
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Figure 4 THC prevents increase in epithelial permeability caused by TNFα. 1
Effect of the corresponding treatments on FD4 dextran paracellular permeability in2
21-day old Calu-3 cells. Epithelial permeability is represented as apparent3
permeability coefficient (Papp) calculated according to the equation in section 2.3.4
Data are presented as mean ± SD; n=9; ***P<0.001 1way ANOVA followed by a5
Bonferroni post-hoc test, compared to vehicle control for THC, (0.3%v/v) EtOH. THC6
+ TNFα treatment is also compared against treatment with TNFα alone. 7
8
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Figure 5 CB2 receptor antagonism prevents effect of THC.1
Effect of basolateral application of either A. the selective CB1 antagonist, AM 2512
(100 nM) or B. the selective CB2 antagonist, SR144528 (100 nM) in the presence of3
THC (30 µM) and TNFα (10 ng/mL). Average basal TEER values were A. 669±5.54
Ω.cm2 and B. 687±5.3 Ω.cm2. Data are expressed as percentage TEER by5
calculating the relative change in resistance at various time points from basal6
reading, and are presented as mean ± SD; n=15, *P<0.05, **P<0.01, ***P<0.001,7
2way ANOVA followed by a Bonferroni post-hoc test, compared to THC + TNFα; 8
except THC +TNFα, which is compared to vehicle control (0.01% v/v) EtOH. 9
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Figure 6 CB receptor agonists prevent TNFα-induced reductions in TEER. 1
Effects of basolateral application of A. Non-selective cannabinoid receptor agonist2
HU-210 (100 nM), selective CB1R agonist ACEA (100 nM) or selective CB2R agonist3
JWH 133 (3 μM) alone and; B. Cannabinoid receptor agonists in the presence of4
TNFα (10 ng/mL). Average basal TEER values were A. 721±4.5 Ω.cm2 and B.5
687±7.2 Ω.cm2. Data are expressed as percentage TEER by calculating the relative6
change in resistance at various time points from basal reading, and are presented as7
mean ± SD; n=9-18, *P<0.05, **P<0.01, ***P<0.001, 2way ANOVA followed by a8
Bonferroni post-hoc test. TEER data were compared to A. vehicle control (0.01%9
v/v) EtOH. B. TNFα (10 ng/mL); except TNFα, which is compared to vehicle control 10
(0.01% v/v) EtOH.11
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Figure 7 Calu-3 cells express CB1 and CB2 receptors.1
Typical immunoblot showing samples that were treated with polyclonal A. anti-CB1 or2
B. anti-CB2 receptor rabbit antibody (green bands). Samples of Calu-3 cells grown at3
ALI were harvested at day 21 of culture; whereas cells of the LLI were lysed at day 54
of culture, when cells were fully confluent in Transwell® inserts. GAPDH (red band)5
was used as a loading control. Blot is representative of 3 separate experiments.6
7
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Figure 8 THC prevents the TNFα-induced reduction in occludin expression.1
A. Typical immunoblot showing expression of occludin in Calu-3 cells treated2
following treatment of TNFα (10 ng/mL), vehicle control (0.3% v/v) EtOH, THC (30 3
μM) alone or in the presence of TNFα in 21-day old Calu-3 cells for 48 hours. Basal 4
represents untreated cells cultured at air-liquid interface; i.e. no drug. B. Data5
presented as mean of fold change to protein expression over vehicle, (0.3% v/v)6
EtOH ± SD; n=3-8, **P<0.01, 1way ANOVA followed by a Bonferroni post-hoc test,7
compared to vehicle control, (0.3% v/v) EtOH, except combined treatment of THC +8
TNFα which is compared to TNFα (10 ng/mL). 9
10
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Figure 9 THC prevents the TNFα-induced reduction in ZO-1 expression. 1
A. Typical immunoblot showing expression of ZO-1 in Calu-3 cells treated following2
treatment of TNFα (10 ng/mL), vehicle control (0.3% v/v) EtOH, THC (30 μM) alone 3
or in the presence of TNFα in 21-day old Calu-3 cells for 48 hours. Basal represents 4
untreated cells cultured at air-liquid interface; i.e. no drug. B. Data presented as5
mean of fold change to protein expression over vehicle, (0.3% v/v) EtOH ± SD; n=3-6
8, *P<0.05, 1way ANOVA followed by a Bonferroni post-hoc test, compared to7
vehicle control, (0.3% v/v) EtOH, except combined treatment of THC + TNFα which 8
is compared to TNFα (10 ng/mL). 9
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